These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23591227)

  • 1. Using the rate of bacterial clearance determined by real-time polymerase chain reaction to evaluate antibiotic effectiveness in Acinetobacter baumannii bacteremia.
    Decker BK; Powers JH
    Crit Care Med; 2013 May; 41(5):e47. PubMed ID: 23591227
    [No Abstract]   [Full Text] [Related]  

  • 2. Using the rate of bacterial clearance determined by real-time polymerase chain reaction as a timely surrogate marker to evaluate the appropriateness of antibiotic usage in critical patients with Acinetobacter baumannii bacteremia.
    Chuang YC; Chang SC; Wang WK
    Crit Care Med; 2012 Aug; 40(8):2273-80. PubMed ID: 22809902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time polymerase chain reaction to evaluate antibiotic appropriateness: should we spread the news to multiply it?
    Van Zanten AR
    Crit Care Med; 2012 Aug; 40(8):2492-3. PubMed ID: 22809917
    [No Abstract]   [Full Text] [Related]  

  • 4. The authors reply.
    Chuang YC; Chang SC; Wang WK
    Crit Care Med; 2013 May; 41(5):e47-8. PubMed ID: 23591228
    [No Abstract]   [Full Text] [Related]  

  • 5. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia.
    Zeng J; Zhang L; Gao M; Wu J; Wu H; Chen J; Chen X; Tang W
    Int J Infect Dis; 2017 Aug; 61():23-26. PubMed ID: 28572073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug-resistant Acinetobacter baumannii bacteremia treated with tigecycline in two pediatric burn patients.
    Kanık-Yüksek S; Tezer H; Ozkaya-Parlakay A; Gulhan B; Sayed-Oskovi H; Kara A; Şenel E
    Pediatr Infect Dis J; 2015 Jun; 34(6):677. PubMed ID: 25970113
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical manifestations, antimicrobial therapy, and prognostic factors of monomicrobial Acinetobacter baumannii complex bacteremia.
    Lee NY; Chang TC; Wu CJ; Chang CM; Lee HC; Chen PL; Lee CC; Ko NY; Ko WC
    J Infect; 2010 Sep; 61(3):219-27. PubMed ID: 20624424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pneumonia- and non-pneumonia-related Acinetobacter baumannii bacteremia: Impact on empiric therapy and antibiotic resistance.
    Teng SO; Yen MY; Ou TY; Chen FL; Yu FL; Lee WS
    J Microbiol Immunol Infect; 2015 Oct; 48(5):525-30. PubMed ID: 25103719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tigecycline for secondary Acinetobacter bacteremia and factors associated with treatment failure.
    Liou BH; Lee YT; Kuo SC; Liu PY; Fung CP
    Antimicrob Agents Chemother; 2015; 59(6):3637-40. PubMed ID: 25824230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
    Ng TM; Teng CB; Lye DC; Apisarnthanarak A
    Infect Control Hosp Epidemiol; 2014 Jan; 35(1):49-55. PubMed ID: 24334798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia.
    Garnacho-Montero J; Amaya-Villar R; Ferrándiz-Millón C; Díaz-Martín A; López-Sánchez JM; Gutiérrez-Pizarraya A
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):769-77. PubMed ID: 25865094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of unforeseen intractable severe bacteremia due to Acinetobacter baumannii--an efficacy of sulbactam--.
    Takahashi N; Shimada T; Tanabe K; Sato M; Kitamura J; Sato H; Yoshitomi H; Ishibashi Y; Sakane T
    Jpn J Infect Dis; 2009 Nov; 62(6):461-3. PubMed ID: 19934540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of reduced tigecycline susceptibility on clinical outcomes of Acinetobacter bacteremia.
    Chang YY; Liu YM; Liu CP; Kuo SC; Chen TL;
    J Microbiol Immunol Infect; 2018 Feb; 51(1):148-152. PubMed ID: 29050749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin efficacy in an experimental model of Acinetobacter baumannii endocarditis.
    Rodríguez-Hernández MJ; Jiménez-Mejias ME; Pichardo C; Cuberos L; García-Curiel A; Pachón J
    Clin Microbiol Infect; 2004 Jun; 10(6):581-4. PubMed ID: 15191391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Epidemiology and Drug Resistance of Acinetobacter baumannii Isolated from Hospitals in Southern Poland: ICU as a Risk Factor for XDR Strains.
    Chmielarczyk A; Pilarczyk-Żurek M; Kamińska W; Pobiega M; Romaniszyn D; Ziółkowski G; Wójkowska-Mach J; Bulanda M
    Microb Drug Resist; 2016 Jun; 22(4):328-35. PubMed ID: 26745326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and outcome analysis of acinetobacter baumannii complex bacteremia in critical patients.
    Lee HY; Chen CL; Wu SR; Huang CW; Chiu CH
    Crit Care Med; 2014 May; 42(5):1081-8. PubMed ID: 24394630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
    Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR
    Clin Microbiol Infect; 2007 Feb; 13(2):196-198. PubMed ID: 17328733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia.
    Lee NY; Lee HC; Ko NY; Chang CM; Shih HI; Wu CJ; Ko WC
    Infect Control Hosp Epidemiol; 2007 Jun; 28(6):713-9. PubMed ID: 17520546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin.
    Michalopoulos A; Kasiakou SK; Rosmarakis ES; Falagas ME
    Scand J Infect Dis; 2005; 37(2):142-5. PubMed ID: 15764204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence in Taiwan of novel imipenem-resistant Acinetobacter baumannii ST455 causing bloodstream infection in critical patients.
    Lee HY; Huang CW; Chen CL; Wang YH; Chang CJ; Chiu CH
    J Microbiol Immunol Infect; 2015 Dec; 48(6):588-96. PubMed ID: 26055692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.